CEACAM8: A Potential Drug Target and Biomarker for Carcinoembryonic Antigen Gene Family Member 8

Target Name: CEACAM8

NCBI ID: G1088

CEACAM8

CEACAM8: A Potential Drug Target and Biomarker for Carcinoembryonic Antigen Gene Family Member 8

Abstract:

Carcinoembryonic antigen (CAA) genes are a family of hematopoietic stem cell-derived antigens that play a crucial role in cancer progression and immune evasion. CEACAM8, a member of the CAA gene family, has been identified as a potential drug target and biomarker for various diseases, including cancer. This article will review the current research on CEACAM8, its potential drug targets, and its potential as a biomarker for cancer diagnosis and treatment.

Introduction:

Carcinoembryonic antigen (CAA) genes are a family of hematopoietic stem cell-derived antigens that have been identified as potential drug targets in various diseases, including cancer. These antigens are expressed in various tissues and have been associated with cancer-related outcomes, including cancer stemness, cancer-related immune evasion, and cancer-related metastasis. CEACAM8, a member of the CAA gene family, has been identified as a potential drug target and biomarker for various diseases, including cancer.

Current Research on CEACAM8:

Several studies have investigated the potential drug targets of CEACAM8. One of the most promising targets is the CEACAM8-CDK4 interaction, which has been shown to promote the growth and survival of cancer cells. This interaction has led to the development of inhibitors that target CEACAM8 and CDK4, leading to the potential for cancer treatment.

Another potential drug target of CEACAM8 is its role in cancer stemness. Cancer stem cells are a subtype of cancer cell that have the ability to maintain their stem-like properties and promote the development of cancer. CEACAM8 has been shown to be involved in the maintenance of cancer stem cells, which may have implications for cancer treatment.

In addition to its potential drug targets, CEACAM8 has also been investigated as a potential biomarker for cancer diagnosis and treatment. Several studies have shown that CEACAM8 is expressed in various tissues and has been associated with cancer-related outcomes, including cancer stemness, cancer-related immune evasion, and cancer-related metastasis. These findings suggest that CEACAM8 may be a useful biomarker for cancer diagnosis and treatment.

Potential Applications of CEACAM8:

The potential applications of CEACAM8 are vast, ranging from cancer treatment to cancer diagnosis and monitoring. One of the most promising applications of CEACAM8 is its potential as a drug target. The development of inhibitors that target CEACAM8 and its associated signaling pathways has the potential to lead to the development of new cancer treatments.

In addition to its potential as a drug target, CEACAM8 has also been shown to be involved in the maintenance of cancer stem cells, which may have implications for cancer treatment. Cancer stem cells are a subtype of cancer cell that have the ability to maintain their stem-like properties and promote the development of cancer. Targeting CEACAM8 may have the potential to disrupt the maintenance of cancer stem cells, leading to the death of cancer stem cells and a reduction in cancer growth.

Another potential application of CEACAM8 is its potential as a biomarker for cancer diagnosis and treatment. Several studies have shown that CEACAM8 is expressed in various tissues and has been associated with cancer-related outcomes, including cancer stemness, cancer-related immune evasion, and cancer-related metastasis. These findings suggest that CEACAM8 may be a useful biomarker for cancer diagnosis and treatment, particularly in the development of new cancer treatments.

Conclusion:

CEACAM8, a member of the CAA gene family, has been identified as a potential drug target and biomarker for various diseases, including cancer. Its role in the maintenance of cancer stem cells and its potential as a drug target and biomarker make it an attractive target for cancer treatment. Further research is needed to fully understand the potential applications of CEACAM8 and its implications for cancer diagnosis and treatment.

Protein Name: CEA Cell Adhesion Molecule 8

Functions: Cell surface glycoprotein that plays a role in cell adhesion in a calcium-independent manner (PubMed:8776764, PubMed:2022629, PubMed:11590190). Mediates heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6 (PubMed:8776764, PubMed:2022629, PubMed:11590190). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764)

The "CEACAM8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets